Unraveling oncogenesis: What makes cancer tick?
Recent discoveries in cancer biology may bring forward an additional collection of tools in physicians’ arsenal of cancer therapeutics. Scientists now know that many cancer-associated mutations affect chromatin regulation and the function of multiprotein transcriptional complexes, which can ultimately lead to cancer development and growth. This knowledge may be used to develop future clinical approaches.
The ASBMB annual meeting is around the corner, and attendees can expect a wide variety of symposia offerings throughout the event. One of the symposia, oncogenic hubs: chromatin regulatory and transcriptional complexes in cancer, will focus on the role of transcriptional dysregulation, histone modification and chromatin regulatory complexes in cancer formation. Cigall Kadoch of Harvard Medical School and Greg Wang of Duke University School of Medicine organized and will lead the session.
Wang, a current Journal of Biological Chemistry editorial board member and 2022 ASBMB Young Investigator Award recipient, said the symposium will focus on cancer but encouraged attendees from all fields to participate in the session.
“These topics can be applied to many other diseases as well,” Wang said.
According to Kadoch, the topics covered at the symposium directly relate to patient care and developing novel therapeutic approaches.
“We’re at a unique moment in time in which the learnings from first-in-class approaches in the clinic are coming back to the bench to inform new questions and propel next-step advances,” Kadoch said. “(We) hope this section of the ASBMB meeting does a good job of covering that.”
Wang added: “(This field) elevates basic science to the translational level to ultimately benefit patients.”
Kadoch and Wang selected a diverse array of speakers who study the role of molecular condensates, extrachromosomal DNA, chromatin regulatory machinery, epigenetics and more in cancer.
“I am particularly excited about the interplay of the speakers within the section and the opportunity for our audiences to take away numerous new approaches to exploring some of the most pressing biological questions relating to oncogenic hubs,” Kadoch said.
Check out the full program schedule to get the most out of #ASBMB25.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreFeatured jobs
from the ASBMB career center
Get the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Differences in pili structure modulate bacterial behavior
Researchers demonstrate how small changes in the structure of hair-like protein appendages can affect the behavior of Acinetobacter bacteria.
Cholesterol regulatory genes predict liver transplant outcomes
Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.
Lipid signatures for a rare neurological disorder
Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.
Disease-linked mutations disrupt protein phase behavior
Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.
The dual role of asprosin in chronic fatty liver disease
Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.
Novel inhibitor targets RAS-driven cancers
Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.